Silence Therapeutics Q2 net loss widens to $27.4M; cash $114.2M, divesiran Phase 2 on track

Silence Therapeutics plc

2025-Q2 EPS reported -$0.39 revenue$366,000

Net loss of $27.4M in Q2 2025 vs $19.8M in Q2 2024; R&D expenses rose to $17.6M.
Cash and short-term investments $114.2M as of June 30, 2025; expected to fund operations into 2028.
Divesiran Phase 2 SANRECO trial >50% enrolled; on track for full enrollment by year-end 2025.
Paused Phase 1 initiation of SLN548 to prioritize extra-hepatic siRNA targeting; preclinical data promising.
Zerlasiran Phase 3 readiness activities completed; seeking partnership for Phase 3 and commercialization.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.